59% of all transmission came pre/asymptomatic transmission,
35% presymptomatic individuals 24% asymptomatic.
Researchers at The University of Hong Kong developed TMP1, an oral drug blocking coronavirus entry and replication.
Tested in mice and hamsters, it was effective against SARS-CoV-2 variants and drug-resistant strains.
“I politely asked her to wear it and told her I was immunocompromised. She rolled her eyes, held the mask in front of her face without actually putting it on. She leaned across me to hit the button, even though there was another set of buttons on the opposite side of the elevator. This felt like a deliberate attempt to violate my personal space and ensure I knew just how unhappy she was that I asked her to mask. As time went on and more people bought into the comfortable lie that COVID was over, it became harder to access safe medical care. Fewer and fewer staff were complying with mandates; eventually mandates were dropped altogether in favour of “mask-friendly” policies.”
“Intranasal protein vaccine with MF59-like adjuvant protects against SARS-CoV-2, including XBB variants.
In mice, it boosts mucosal immunity with durable neutralizing antibodies.”
“As caught by @michael_hoerger,
CDC just modified their dashboard to make Covid transmission look lower on November 18, 2024.
‘The underlying data are identical. However, the Y axis is rescaled to make everything seem lower.’”
“We analyzed the deaths of United States Politicians during the #COVIDPandemic & found some interesting statistics.
From 2020-2024 (into November) at least 466 active (or recently active) politicians, judges, & the like passed away. “
COVID-19 hitches a ride on mucus to spread deep into lungs, live imaging shows.
Investigators observed that the movement of mucus can spread the COVID-19 virus inside the respiratory tract, where it later forms aerosols that infect other people.
PICOBOO randomized trial, evaluating second boosters after mRNA priming. 1) novavax is more durable 2) mRNA vaccines have higher antibody responses 3) novavax has fewer side effects
Pfizer antibody levels drop around 40% between 1 month to 3 months post vax. Moderna is less, w/ a 14% drop in younger adults, 26% decline in older adults. Novavax had only a 3% decline in younger adults and 17% in older adults.
“(🧵It's the Сονіd, ѕtυріd!): Viewing the US election through the lens of the ongoing ЅАRЅ-Соν-2 раndеmіc.
(My hot take on what happened, and where things are headed. Prelude to the final 🧵in the "How does it end" series)…
…No country can expect sustained 3% growth, if 3% of its workforce drops out every year.
There is no path forward - for the US or any other country - without addressing this. Repeated covid infections are not a sustainable situation.”
“Thread: Public Comment on HICPAC Concerns 🧵
1/ I’m here not to address HICPAC directly, but to speak to those listening—healthcare professionals, patients, and advocates—who are committed to public health and safety.
Let me highlight several critical concerns.”
November 12, 2024
“Between October 27 and November 2, wastewater sampling from New Mexico revealed ‘very high’ levels of the virus, with ‘high’ levels being detected in Oregon, Arkansas, and Maine, according to the U.S. Centers for Disease Control and Prevention (CDC).”
“Epidemic vs. endemic vs. pandemic
To understand why the COVID-19 pandemic isn’t over, let’s do a quick refresher on the definitions of ‘epidemic,’ ‘endemic’ and ‘pandemic.’
“Imagine the impact over the next decade. This isn’t just about individuals; it’s a 10% chance of our doctors, pilots, presidents, soldiers, and police officers all grappling with the debilitating effects of Long COVID. When essential roles in society are consistently compromised, the risks are stacked like blocks in an increasingly unstable tower—one that can only lean so far before it topples. The more we ignore the impact of Long COVID, the closer we edge toward this collapse.
The toll of Long COVID is not a hypothetical future but an unfolding reality. As it affects more people, it strains every facet of society—healthcare, insurance rates, disability programs, and economic productivity. “
